Kenneth A. Thomas

University of Calgary — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

49h-index10.3kcitations123works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(32), Fibroblast Growth Factor Research(31), Cancer, Hypoxia, and Metabolism(29), Physics of Superconductivity and Magnetism(11), HER2/EGFR in Cancer Research(10)

Publications123 total

Beyond Conventional Models: Recreating the Initiation, Evolution, and Genome of GBM
2019Open Access
The Seasonal Abundance and Distribution of the Bivalve <i>Lyonsia hyalina</i> (Anomalodesmata: Pandoracea) on a Disturbed New England Mudflat
Northeastern Naturalist·2017
Engineered FGF-1 derivatives as protective agents in nitrogen mustard induced corneal injury
2017
Angiogenesis
Elsevier eBooks·2016
Angiogenesis
Elsevier eBooks·2015· 11 cited
Vascular Endothelial Growth Factor Receptors
Encyclopedia of Biological Chemistry·2013· 6 cited
Immunohistochemical Detection of Antitumor, Antimetastasis, and Antiangiogenesis Effects of a Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor in an Orthotopic Breast Cancer Metastasis Model
Journal of Histotechnology·2010· 1 cited
Abstract 2048: Angiogenesis Protein Therapy With Human Fibroblast Growth Factor (fgf-1): Results Of A Phase I Open Label, Dose Escalation Study In Subjects With CAD Not Eligible For PCI Or CABG
Circulation·2007· 5 cited
Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes
Diabetes Obesity and Metabolism·2006· 138 cited
In his December 25 column of Connecticut Post, William A. Collins once again provided his imaginative overview of the medical liability insurance crisis.
PubMed·2006
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase
Bioorganic & Medicinal Chemistry Letters·2005· 35 citedOpen Access
Potent <i>N</i>-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel
Journal of Medicinal Chemistry·2004· 60 citedOpen Access
Dynamic Contrast-Enhanced MRI Measurements of Passive Permeability through Blood Retinal Barrier in Diabetic Rats
Investigative Ophthalmology & Visual Science·2004· 65 cited
A Novel, Orally–Bioavailable KDR Kinase Inhibitor Decreases Neovascularization in Animal Models of Microvascular Disease
Investigative Ophthalmology & Visual Science·2004
The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase
Bioorganic & Medicinal Chemistry Letters·2004· 36 citedOpen Access
Novel Flt-3/KDR inhibitor is effective against activated Flt-3 and is cytotoxic against Flt-3-driven leukemias in vitro and in vivo
Cancer Research·2004
Property-Based Design of KDR Kinase Inhibitors
Current Medicinal Chemistry·2004· 35 cited
A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth <b> <i>in Vivo</i> </b>
Cancer Research·2004· 26 cited
Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR
Bioorganic & Medicinal Chemistry Letters·2004· 42 citedOpen Access
Vascular Endothelial Growth Factor Receptors
Encyclopedia of Biological Chemistry·2004
page 1 of 7Next →

Frequent Co-authors

Jerry DiSalvo(11), Guillermo Giménez‐Gallego(10), Richard Kendall(5), Greg Conn(5), Xianzhi Mao(4), William R. Huckle(4), M Rios-Candelore(4), Rosemary C. McFall(4), Kathleen Coll(4), David L. Linemeyer(4), Corey K. Goldman(3), David Richardson(3), Kathleen A. Sullivan(3), Gideon A. Rodan(3), Sevgi B. Rodan(3), D.D. Soderman(3), Marie‐Therese Schaeffer(3), Victor B. Hatcher(3), Ruth Z. Rutledge(3), Andrew J. Tebben(3)